53 reports of this reaction
1.6% of all NITROUS OXIDE reports
#11 most reported adverse reaction
HYPERTHERMIA MALIGNANT is the #11 most commonly reported adverse reaction for NITROUS OXIDE, manufactured by AGL Welding Supply Co., Inc.. There are 53 FDA adverse event reports linking NITROUS OXIDE to HYPERTHERMIA MALIGNANT. This represents approximately 1.6% of all 3,365 adverse event reports for this drug.
Patients taking NITROUS OXIDE who experience hyperthermia malignant should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTHERMIA MALIGNANT is a less commonly reported adverse event for NITROUS OXIDE, but still significant enough to appear in the safety profile.
In addition to hyperthermia malignant, the following adverse reactions have been reported for NITROUS OXIDE:
The following drugs have also been linked to hyperthermia malignant in FDA adverse event reports:
HYPERTHERMIA MALIGNANT has been reported as an adverse event in 53 FDA reports for NITROUS OXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTHERMIA MALIGNANT accounts for approximately 1.6% of all adverse event reports for NITROUS OXIDE, making it a notable side effect.
If you experience hyperthermia malignant while taking NITROUS OXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.